Moving Away from Chemotherapy to Treat HR-Positive/HER2-Negative Metastatic Breast Cancer


Looking at new data from the phase 3 PEARL trial, Dr. Melissa K. Accordino discusses how the use of CDK4/6 inhibitors could help patients with HR-positive/HER2-negative metastatic breast cancer move away from chemotherapy.

The use of CDK4/6 inhibitor Ibrance (palbociclib), in combination with either Aromasin (exemestane), which is an estrogen modulator, or the chemotherapy Faslodex (fulvestrant), shows promise for patients with hormone receptor (HR)—positive, HER2-negative metastatic breast cancer, according to Dr. Melissa K. Accordino.

Accordino, assistant professor of medicine in the Division of Hematology/Oncology at the Herbert Irving Comprehensive Cancer Center and Columbia University Medical Center, discussed the findings of the phase 3 PEARL trial in an interview with OncLive®, a sister publication to CURE®, that looked at data that showed no difference in efficacy in progression free survival (PFS) in both arms of the trial. Moreover, patients on the CDK4/6 inhibitor and endocrine therapy demonstrated that this treatment may be safer than the use of chemotherapy.

Accordino hopes that this data helps physicians move away from chemotherapy in this patient population where possible.


The PEARL trial was looking to see in patients who've had endocrine therapy in the metastatic setting, which is more effective palbociclib, which is the CDK4/6 inhibitor, with either exemestane or fulvestrant compared to capecitabine, which is chemotherapy.

That study shows that there really wasn't a difference in advocacy in regards to progression free survival, but the side effect profiles were a little bit different, but what this tells us is among those patients who have already progressed on endocrine therapy, that a CDK4/6 inhibitor and endocrine therapy might be an option over chemotherapy. So, we don't always have to rush to chemotherapy.

The time to response was also similar in both of those arms, which is reassuring. Chemotherapy is definitely an option for our patients. And as our patients are living longer and longer, we're now able to give more and more treatment. I think though, as this data suggests, we should try and exhaust all other options before reaching for chemotherapy, if it makes sense for our patients.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Related Content